Multicenter phase 2 trial of rivoceranib for recurrent or metastatic adenoid cystic carcinoma

A phase 2 trial at centers in the United States and South Korea evaluated the vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor rivoceranib in patients with recurrent or metastatic adenoid cystic carcinoma. Most patients had distant metastasis (92.5%) and received prior systemic treatment (61.3%). According to blinded independent review the ORR was 9.7% (95% CI 4.0-19.0), the median duration of response was 7.2 months (3.5-8.4), and the median progression-free survival was 9.0 months (7.7-11.5). Grade 3 or higher adverse events occurred in 70.0% of patients. Four grade 5 events occurred, with one attributed to rivoceranib (epistaxis). Twenty percent discontinued rivoceranib due to toxicity. The authors conclude that in patients with R/M ACC, rivoceranib had antitumor activity and manageable safety.